Lyrica as monotherapy is positive in Epilepsy

The Lyrica (pregabalin) epilepsy study- A0081047 entitled �A Double-Blind, Randomized, Multicenter Efficacy and Safety Study of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures� Data Monitoring Committee (DMC) has completed their review of the interim analysis. The DMC recommended that the study be stopped based on positive findings for the primary efficacy endpoint. Pfizer has accepted the DMC�s recommendation and has stopped the study. Additional details will be made public when the double-blind code for the study has been appropriately released for general analyses to be conducted. Lyrica is also indicated for Fibromyalgia (in USA )and Neuropathic Pain.